Femasys Inc. (FEMY)
| Market Cap | 24.96M |
| Revenue (ttm) | 1.26M |
| Net Income (ttm) | -18.10M |
| Shares Out | 22.90M |
| EPS (ttm) | -0.83 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 77,213 |
| Open | 1.100 |
| Previous Close | 1.100 |
| Day's Range | 1.085 - 1.125 |
| 52-Week Range | 0.734 - 2.400 |
| Beta | -2.89 |
| Analysts | Strong Buy |
| Price Target | 10.00 (+817.43%) |
| Earnings Date | Nov 12, 2024 |
About FEMY
Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially w... [Read more]
Financial Performance
In 2023, Femasys's revenue was $1.07 million, a decrease of -11.13% compared to the previous year's $1.21 million. Losses were -$14.25 million, 25.0% more than in 2022.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for FEMY stock is "Strong Buy." The 12-month stock price forecast is $10.0, which is an increase of 817.43% from the latest price.
News
Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment
Trial results demonstrated safety and effectiveness of FemaSeed intratubal insemination with high satisfaction ratings from both practitioners and patients Trial results demonstrated safety and effect...
Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update
Company accelerated commercialization with significant new partnerships both in the U.S. and Europe Company accelerated commercialization with significant new partnerships both in the U.S. and Europe
Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control
FemBloc issued patent provides additional coverage for Femasys' therapeutic option for women seeking permanent birth control FemBloc issued patent provides additional coverage for Femasys' therapeutic...
Femasys to Exhibit at ASRM 2024 and Participate in the Congress' KEEPR Education Program
Company's VP of Education and Global Training Named Chairman of ASRM Corporate Member Council Company's VP of Education and Global Training Named Chairman of ASRM Corporate Member Council
Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments
ATLANTA, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-off...
Femasys Announces Infertility Clinic Customers from Coast to Coast
Leading medical clinics become key regional resources to offer FemaSeed infertility treatment Leading medical clinics become key regional resources to offer FemaSeed infertility treatment
Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market
Company taps Comercial Medico Quirurigca, SA and Durgalab as first EU distributors for its CE-marked women's reproductive healthcare products Company taps Comercial Medico Quirurigca, SA and Durgalab ...
Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check
In addition to 510(k) clearance, FemChec, a contrast generating product, is an integral part of the confirmation test following administration of FemBloc non-surgical permanent birth control, currentl...
Femasys to Exhibit at The Canadian Fertility and Andrology Society's 70th Annual Meeting
ATLANTA, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-of...
Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference
ATLANTA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-of...
Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution
ATLANTA, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-offic...
Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters
The Congresswoman representing Georgia's 7th district in the U.S. House of Representatives toured Femasys' facilities to gain a better understanding of our advancements for women's reproductive health...
Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update
Company gained CE Mark approval for four of its women's health products and completed buildout of commercial team for its infertility portfolio Company gained CE Mark approval for four of its women's ...
Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam
Leading women's reproductive health conference directly follows the company's EU CE Mark approval for four of its products Leading women's reproductive health conference directly follows the company's...
Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative
Lee-Sepsick Discussed Company's FemCerv® Endocervical Tissue Sampler and its Role in Cervical Cancer Diagnosis Lee-Sepsick Discussed Company's FemCerv® Endocervical Tissue Sampler and its Role in Cerv...
Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Gender Policy Council
Lee-Sepsick Discussed Atlanta-Based Biomedical Company's Women's Reproductive Health Products Lee-Sepsick Discussed Atlanta-Based Biomedical Company's Women's Reproductive Health Products
Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update
-- Recruitment of the commercial team for our infertility portfolio and the pivotal trial of FemBloc ® for permanent non-surgical birth control continues -- ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) -- F...
Femasys Expands Commercial Management Team with Addition of Experienced New Hires
Team to Drive Strategic Initiatives, Launching Efforts at 2024 ACOG Meeting Team to Drive Strategic Initiatives, Launching Efforts at 2024 ACOG Meeting
Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women's Healthcare Initiatives
ATLANTA, April 18, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-offi...
Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update
Following FDA Clearance of FemaSeed®, Company Secures Capital to Support Commercial Initiatives; Cash Expected to Fund Operations Into 2H 2025 Following FDA Clearance of FemaSeed®, Company Secures Cap...
Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape
-- CEO Kathy Lee-Sepsick and Chief Medical Officer James Liu to Join Jones Trading Analyst Catherine Novack in a Conversation on Current Treatment Options in Infertility Including FemaSeed® at 1PM ET ...
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility
-- In the severe male factor cohort, findings show 24% of women became pregnant after FemaSeed -- -- FemaSeed pregnancy rate by cycle was more than double historic intrauterine insemination (IUI) rate...
Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution
-- Paving the way forward for the broader commercial availability of FemaSeed, an accessible, safe, and cost effective alternative to IVF -- -- Ongoing uncertainty following recent Alabama Supreme Cou...
Femasys' FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF
-- Femasys readies for the commercial launch of FemaSeed ® in the U.S. amidst the uncertainty following the Alabama Supreme Court Ruling on how to handle embryos used for in vitro fertilization (IVF) ...
Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer
-- Seasoned sales and marketing executive with 25 years of experience leading public and private healthcare companies throughout various stages of commercialization will lead commercial launch of Fema...